← Back to All US Stocks

Palatin Technologies Inc. (PTN) Stock Fundamental Analysis & AI Rating 2026

PTN Pharmaceutical Preparations NJ CIK: 0000911216
Recently Updated • Analysis: Apr 14, 2026 • SEC Data: 2025-12-31
STRONG SELL
95% Conf
Pending
Analysis scheduled

📊 PTN Key Takeaways

Revenue: $9.0M
Net Margin: -28.9%
Free Cash Flow: $-6.4M
Current Ratio: 2.76x
Debt/Equity: 0.00x
EPS: $-1.47
AI Rating: STRONG SELL with 95% confidence
Palatin Technologies Inc. (PTN) receives a STRONG SELL rating with 95% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $9.0M, net profit margin of -28.9%, and return on equity (ROE) of -22.6%, Palatin Technologies Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete PTN stock analysis for 2026.

Is Palatin Technologies Inc. (PTN) a Good Investment?

Claude

Palatin Technologies faces existential financial distress with revenue collapsing 100% year-over-year to $9M while incurring -$2.7M operating losses and -$6.4M negative free cash flow. Despite a $14.5M cash position providing ~2.3 years runway, the complete revenue decline and persistent unprofitability in the pharmaceutical sector indicate fundamental business failure with minimal recovery prospects.

Why Buy Palatin Technologies Inc. Stock? PTN Key Strengths

Claude
  • + Strong cash position of $14.5M with zero long-term debt providing financial flexibility
  • + Low capital intensity with minimal capex ($12.8K) reducing ongoing infrastructure burden
  • + Solid short-term liquidity with 2.76x current and quick ratios ensuring near-term solvency

PTN Stock Risks: Palatin Technologies Inc. Investment Risks

Claude
  • ! Catastrophic revenue collapse (-100% YoY) indicating product failure or market exit in critical pharmaceutical business
  • ! Negative free cash flow of -$6.4M annually with only ~2.3 years of cash runway before potential insolvency
  • ! Persistent operating losses (-$2.7M) with -29.8% operating margin demonstrating unsustainable business model
  • ! Zero insider Form 4 filings in 90 days suggesting complete absence of management confidence
  • ! Pharmaceutical sector exposure without apparent revenue-generating products or viable pipeline

Key Metrics to Watch

Claude
  • * Monthly cash burn rate and remaining runway duration to insolvency
  • * Sequential quarterly revenue trends and any pipeline advancement announcements
  • * Form 4 insider transaction filings indicating management confidence in turnaround

Palatin Technologies Inc. (PTN) Financial Metrics & Key Ratios

Revenue
$9.0M
Net Income
$-2.6M
EPS (Diluted)
$-1.47
Free Cash Flow
$-6.4M
Total Assets
$17.9M
Cash Position
$14.5M

💡 AI Analyst Insight

Strong liquidity with a 2.76x current ratio provides a solid financial cushion.

PTN Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin -29.8%
Net Margin -28.9%
ROE -22.6%
ROA -14.4%
FCF Margin -71.8%

PTN vs Healthcare Sector: How Palatin Technologies Inc. Compares

How Palatin Technologies Inc. compares to Healthcare sector averages

Net Margin
PTN -28.9%
vs
Sector Avg 12.0%
PTN Sector
ROE
PTN -22.6%
vs
Sector Avg 15.0%
PTN Sector
Current Ratio
PTN 2.8x
vs
Sector Avg 2.0x
PTN Sector
Debt/Equity
PTN 0.0x
vs
Sector Avg 0.6x
PTN Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Palatin Technologies Inc. Stock Overvalued? PTN Valuation Analysis 2026

Based on fundamental analysis, Palatin Technologies Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-22.6%
Sector avg: 15%
Net Profit Margin
-28.9%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Palatin Technologies Inc. Balance Sheet: PTN Debt, Cash & Liquidity

Current Ratio
2.76x
Quick Ratio
2.76x
Debt/Equity
0.00x
Debt/Assets
36.0%
Interest Coverage
-1,332.42x
Long-term Debt
$0.0

PTN Revenue & Earnings Growth: 5-Year Financial Trend

PTN 5-year financial data: Year 2021: Revenue $118.0K, Net Income -$22.4M, EPS N/A. Year 2022: Revenue $1.5M, Net Income -$33.6M, EPS N/A. Year 2023: Revenue $4.9M, Net Income -$36.2M, EPS N/A. Year 2024: Revenue $4.9M, Net Income -$24.0M, EPS N/A. Year 2025: Revenue $4.5M, Net Income -$29.7M, EPS $-101.16.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Palatin Technologies Inc.'s revenue has grown significantly by 3,706% over the 5-year period, indicating strong business expansion. The most recent EPS of $-101.16 indicates the company is currently unprofitable.

PTN Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-71.8%
Free cash flow / Revenue

PTN Quarterly Earnings & Performance

Quarterly financial performance data for Palatin Technologies Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q2 2026 $116.0K -$2.4M $-1.47

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Palatin Technologies Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$6.4M
Cash generated from operations
Capital Expenditures
$12.8K
Investment in assets
Dividends
None
No dividend program

PTN SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Palatin Technologies Inc. (CIK: 0000911216)

📋 Recent SEC Filings

Date Form Document Action
Feb 17, 2026 10-Q form10-q.htm View →
Jan 2, 2026 4 xslF345X05/ownership.xml View →
Jan 2, 2026 4 xslF345X05/ownership.xml View →
Dec 29, 2025 4 xslF345X05/ownership.xml View →
Dec 11, 2025 4 xslF345X05/ownership.xml View →

Frequently Asked Questions about PTN

What is the AI rating for PTN?

Palatin Technologies Inc. (PTN) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.

What are PTN's key strengths?

Claude: Strong cash position of $14.5M with zero long-term debt providing financial flexibility. Low capital intensity with minimal capex ($12.8K) reducing ongoing infrastructure burden.

What are the risks of investing in PTN?

Claude: Catastrophic revenue collapse (-100% YoY) indicating product failure or market exit in critical pharmaceutical business. Negative free cash flow of -$6.4M annually with only ~2.3 years of cash runway before potential insolvency.

What is PTN's revenue and growth?

Palatin Technologies Inc. reported revenue of $9.0M.

Does PTN pay dividends?

Palatin Technologies Inc. does not currently pay dividends.

Where can I find PTN SEC filings?

Official SEC filings for Palatin Technologies Inc. (CIK: 0000911216) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is PTN's EPS?

Palatin Technologies Inc. has a diluted EPS of $-1.47.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is PTN a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Palatin Technologies Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is PTN stock overvalued or undervalued?

Valuation metrics for PTN: ROE of -22.6% (sector avg: 15%), net margin of -28.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy PTN stock in 2026?

Our dual AI analysis gives Palatin Technologies Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is PTN's free cash flow?

Palatin Technologies Inc.'s operating cash flow is $-6.4M, with capital expenditures of $12.8K. FCF margin is -71.8%.

How does PTN compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -28.9% (avg: 12%), ROE -22.6% (avg: 15%), current ratio 2.76 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 14, 2026 | Data as of: 2025-12-31 | Powered by Claude AI